1. Introduction {#sec1}
===============

Hepatitis is a serious issue facing the global health care community, with the hepatitis B virus (HBV) and hepatitis C virus (HCV), in particular, accounting for 96% of all hepatitis mortalities. As reported by World Health Organization (WHO) in 2015, an estimated 257 million people suffered from chronic hepatitis B (CHB) worldwide, while 71 million people suffered from chronic hepatitis C (CHC) \[[@B1]\].

According to two previous nationwide cohort studies investigating CHB and CHC patients in Taiwan, the risk of developing chronic kidney disease (CKD) was approximately 2.3-folds higher in the CHB cohort compared with the non-CHB cohort, while that risk was 1.66-fold higher in the CHC cohort than the non-CHC cohort \[[@B2], [@B3]\], indicating that chronic hepatitis patients have an elevated risk of developing CKD. Moreover, hepatitis patients associated with CKD will present enhanced obstacles to treatment, and an increased mortality rate, both of which further increase the economic burden placed on health care systems.

HBV infection not only affects liver function but also induces HBV-associated glomerulonephritis with several renal manifestations, particularly membranous nephropathy (MN). The HBV may interact with pre-existing host factors leading to a possible increase in morbidity and mortality \[[@B4]\]. HCV infection increases the risks of developing CKD and progression to end-stage renal failure (ESRF), associated with an elevated mortality rate observed in kidney dialysis and transplant recipients. Meanwhile, Solid et al. found that CHC patients with CKD G1-G5 and end-stage renal disease (ESRD) demonstrate a three-fold increased mortality rate than non-CKD patients. In a separate study of dialysis patients, the HCV cohort exhibited a higher adjusted hazard ratio (aHR) for mortality than the non-HCV cohort \[[@B5], [@B6]\].

Medical options for the treatment of CHB generally range from the injected form of interferon-*α* to the oral forms of nucleoside analogs (NAs). NAs used in the treatment of CHB patients are generally considered effective and convenient due to their oral administration and aside from telbivudine, exhibit minimal negative effects on renal function \[[@B7], [@B8]\]. However, with progression to CKD, interferon-*α* is not suitable due to poor tolerance, injection risks, and low effectiveness. Some NAs must be adjusted according to renal function (creatinine clearance \<50 mL/min), and nephrotoxicity with adefovir and tenofovir treatments must be considered \[[@B8], [@B9]\].

For the decade prior to the development of direct-acting antivirals (DAAs), interferons (IFN), or Peginterferons (PEG-IFN) combined with ribavirin were the primary therapeutic modalities for HCV. Early DAAs, prevalent from 2011 to 2013, still required combination with PEG-IFN \[[@B10]\]. Both IFN and ribavirin are metabolized through the kidneys, thus increasing the complexity of treating HCV patients with CKD, and demonstrate poor effectiveness when associated with ESRF and hemodialysis \[[@B11]\].

Due to enhanced treatment complexity, the management of hepatitis patients with CKD will inevitably result in higher medical expenses incurred by health care systems. A U.S. study reported that the health care utilization rate was higher for CHB-CKD patients, with financial expenditures 3 to 5 times higher compared to non-CKD CHB patients \[[@B12]\]. Furthermore, a retrospective cohort study of 35,965 HCV patients concluded that HCV patients with CKD had higher health care utilization rates and medical costs \[[@B5]\]. A separate retrospective cohort study of 3,438 HCV patients receiving oral DAAs revealed that those with CKD also incurred higher health care costs compared with non-CKD HCV patients \[[@B13]\].

The development of new NAs and DAAs has significantly increased the response rate for both HBV and HCV patients with CKD; however, there are limitations primarily related to their high expenses. As such, patients in Taiwan often seek complementary therapy from TCM, which is widely covered by the National Health Insurance system. Previous studies have revealed that nearly 37% of patients with HBV and 66% of patients with HCV utilized Chinese herbal medicine (CHM) as an adjuvant therapy in Taiwan \[[@B14], [@B15]\]. In addition, a recent study has suggested that CHM could be considered an effective adjunct to prolong the lifespan of patients with CKD \[[@B16]\]. However, despite the increased popularity of CHM as complimentary therapy, it remains unclear whether CHM can prevent the development of CKD in patients suffering from CHB and CHC.

Thus, the aim of the present study is to investigate CKD incidence among CHB and CHC patients between a CHM and non-CHM cohort by analyzing one million cases recorded in the Longitudinal Health Insurance Database (LHID2010) of the Taiwan NHIRD. Furthermore, we have collected and analyzed the associated CHM prescription patterns to provide prescription guidance for clinical practitioners and direction for future research.

2. Materials and Methods {#sec2}
========================

2.1. Data Source {#sec2.1}
----------------

The Taiwan National Health Insurance (NHI), covering more than 99% of the population, set up the National Health Insurance Research Database (NHIRD) in 1995. The database contains outpatient treatment records, various hospitalization data, prescribed medications, and other medical data for each case; importantly, the database records of outpatient visits also include TCM outpatient service.

For this study, data from the Longitudinal Health Insurance Database (LHID) were used, which randomly selects one million subjects from the NHIRD, containing cases with age and gender distributions similar to the original database. To ensure the privacy of individuals, identification numbers are encrypted before the database is released. The diagnoses are coded according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). The Research Ethics Committee of China Medical University and Hospital in Taiwan approved this study (CMUH-104-REC2-115-R3).

2.2. Study Population {#sec2.2}
---------------------

The population included in this study were patients newly diagnosed with hepatitis (HBV, ICD-9-CM: 070.22, 070.23, 070.32, 070.33, and V02.61; HCV, ICD-9-CM: 070.41, 070.44, 070.51, 070.54, and V02.62) during the period of 2000 to 2010. The CHM users were defined as patients with at least 30 days prescription of CHM, and the first date of CHM prescription was set as index date during 2000 to 2012. We then categorized the hepatitis patients into two cohorts, with or without use of CHM after hepatitis diagnosis. All subjects selected were over 18 years of age and followed up to CKD occurrence, The expired date was set as the patients was dead, withdrawn by NHIRD or out of Dec 31, 2013.

2.3. Primary Outcome {#sec2.3}
--------------------

The primary outcome of this study was patients newly diagnosed with CKD (ICD-9-CM: 250.4, 274.1, 283.11, 403.1, 404.2, 404.3, 440.1, 442.1, 447.3, 572.4, 580--588, 642.1, and 646.2) after hepatitis diagnosis. As the risk of outcome may be influenced by comorbidities and the usage of the medicine, histories of hypertension (ICD-9-CM: 401--405), diabetes mellitus (ICD-9-CM: 250), coronary artery disease (ICD-9-CM: 410--414), hyperlipidemia (ICD-9-CM: 272.0, 272.1, 272.2, 272.4), cirrhosis (ICD-9-CM: 571.2, 571.5, 571.6), congestive heart failure (ICD-9-CM: 428.0), osteoporosis (ICD-9-CM: 733.0, 733.1), arrhythmia (ICD-9-CM: 427.89, 427.9), peripheral vascular disease (ICD-9-CM: 443.89, 443.9), HBV drugs (lamivudine, adefovir, entecavir, telbivudine, and tenofovir), HCV drugs (peginterferon), CKD drugs (dipyridamole, pentoxifylline, acei, arb, ccb, acetylcysteine, allopurinol, febuxostat, benzbromarone, vitamin D), DM drugs (metformin, DPP4, sulfonylureas, TZD, other anti-DM drugs) and statin were included as covariates; meanwhile, age, gender, and urbanization were demographic factors adjusted in this study.

2.4. Matching {#sec2.4}
-------------

For each newly diagnosed chronic hepatitis patient with CHM treatment, we used propensity score matching at 1 : 1 to select the corresponding matched non-CHM users. Propensity score calculated the probability by using the logistic regression model and the variables including age, gender, urbanization, comorbidities, and medications mentioned above.

2.5. Statistical Analyses {#sec2.5}
-------------------------

To compare the differences in demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts, chi-squared test and *t*-test were used for category and continuous variables, respectively. We then calculated the risk of CKD between CHM and non-CHM cohorts. The crude and adjusted Cox proportional hazard models were demonstrated by hazard ratios (HRs) and aHRs with 95% confidence intervals (CIs). The Kaplan--Meier method was applied to measure cumulative incidence curves, and the log-rank test was used to evaluate the difference between the two curves and plotted by R studio (3.5.2). The network plot analysis by the open source free software, NodeXL (<http://nodexl.codeplex.com/>), revealed the associations of any two herbs and CHM formulas. The statistical analysis ran with type I error *α* = 0.05 using the statistical software package, SAS, version 9.4 (SAS Institute, Inc., Cary, NC).

3. Results {#sec3}
==========

3.1. Demographic Characteristics {#sec3.1}
--------------------------------

Of the one million individual cases recorded in the LHID, 19,409 adults diagnosed with hepatitis between 2000 and 2010 were identified. After exclusion criteria and determination of CHM use, those patients were classified into two groups, CHM and non-CHM users. With propensity score matching by sex, age, urbanization, comorbidities, and medications, the CHM and non-CHM cohorts each consisted of 2,710 subjects ([Figure 1](#fig1){ref-type="fig"}). The study population of CHM users and non-CHM users, shown in [Table 1](#tab1){ref-type="table"}, were approximately 60% male with a mean age of 53.2 years. In terms of medication use, more than 50% of hepatitis patients were treated for CKD, followed by diabetes mellitus (DM). The only covariate which showed a significant difference between the two groups was age (*p* value = 0.01).

3.2. The Risk Factors and Cumulative Incidence of CKD in Patients with Hepatitis {#sec3.2}
--------------------------------------------------------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, patients diagnosed with CKD after hepatitis diagnosis were filtered out, and Cox model was used to adjust the HR of CKD incidence. The results of the study revealed that 318 hepatitis patients in the non-CHM cohort, and 452 patients in the CHM cohort developed CKD. After adjustment for gender, age, urbanization, comorbidities, and medications, patients in the CHM cohort exhibited a lower cumulative incidence of CKD (aHR = 0.69, *p* value ≤0.001, 95% CI = 0.59--0.8) in comparison with the non-CHM cohort. Of note, males had a higher risk of developing CKD, while age was also found to be highly correlated to increased incidence of CKD.

With regards to comorbidities, patients with heart failure (aHR = 1.61, 95% CI = 1.23--2.11), diabetes mellitus (aHR = 1.55, 95% CI = 1.31--1.84), liver cirrhosis (aHR = 1.54, 95% CI = 1.29--1.83), and hypertension (aHR = 1.36, 95% CI = 1.14--1.62) demonstrated significant differences (*p* value \<0.001) in the development of CKD. It is worth noting that only DM medication increased the risk of developing CKD among hepatitis patients (aHR = 1.41, 95% CI = 1.18--1.68, *p* value \<0.001). HBV drugs had no significant effect to prevent development of CKD (*p* value = 0.15); however, HCV, statin, and CKD medications reduced the risk of developing CKD in patients with hepatitis.

Multivariable stratified analyses were applied to verify the association of hepatitis patients with CHM treatment to reduce CKD risk for those comorbidities. The results demonstrated statistical significance for hepatitis patients associated without or with these comorbidities including hypertension (aHR = 0.69, 95% CI = 0.54--0.88; aHR = 0.70, 95% CI = 0.58--0.85), diabetes (aHR = 0.73, 95% CI = 0.60--0.90; aHR = 0.67, 95% CI = 0.54--0.84), liver cirrhosis (aHR = 0.79, 95% CI = 0.67--0.94; aHR = 0.50, 95% CI = 0.36--0.68), and heart failure (aHR = 0.73, 95% CI = 0.62--0.85; aHR = 0.51, 95% CI = 0.31--0.86) between these two cohorts. These results indicate that CHM significantly decreases the CKD risk in hepatitis patients associated with or without comorbidities including hypertension, diabetes mellitus, liver cirrhosis, and heart failure (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}).

Additionally, the cumulative incidence of CKD, as calculated by the Kaplan--Meier method, revealed a significant difference (*p* value \<0.05) between the CHM cohort and the non-CHM cohort in patients with hepatitis ([Figure 2](#fig2){ref-type="fig"}), indicating that the CHM cohort indeed had a lower cumulative incidence of CKD compared with the non-CHM cohort.

In order to clarify whether a specific type of hepatitis benefitted more from CHM, we further analyzed the HR of HBV, HCV, and HBV/HCV coinfection patients, as shown in [Table 3](#tab3){ref-type="table"}. Notably, we found that CHM had reduced the risk of CKD incidence in the HCV (*p* \< 0.001) and HBV/HCV coinfection (*p* \< 0.05) subgroups; meanwhile, the aHR of the HBV subgroup was 0.81, demonstrating no statistical significance (*p* \> 0.05). Furthermore, CHM users among hepatitis patients had longer follow-up periods represented by higher person years (15533 PY) compared with those in non-CHM cohort (9069 PY). This finding indicates that CHM may provide more protective effects to the renal function of CHC patients in particular, thereby reducing the risk of developing CKD. Considering the combination treatment of CHM and western medicine in HBV, HCV, and HBV/HCV coinfection patients ([Table 4](#tab4){ref-type="table"}), HCV patients with western medicine (HCV drugs) treatment only (aHR = 0.66, 95% CI = 0.53--0.81), and patients receiving both CHM and HCV western medicine treatment (aHR = 0.40, 95% CI = 0.21--0.76) had significantly decreased risk of developing CKD. This indicates that CHM may indeed alleviate the risk of CKD in HCV patients.

In this study, the CHM users were defined as with at least 30 days prescription of CHM after hepatitis diagnoses. In [Table 5](#tab5){ref-type="table"}, we stratified the prescription days of CHM users into 30 to 60 days, 60 to 90 days, and more than 90 days. We discovered that CHM users with at least 90 days of CHM consumption had significant lower risk of developing CKD compared with non-CHM users (aHR = 0.58, 95% CI = 0.49--0.69). Besides, there was a trend effect with lower CKD risk in parallel with CHM consumption periods (*p* for trend \<0.001).

3.3. Top Ten Single Herbs and Formulas {#sec3.3}
--------------------------------------

The top ten single herbs and formulas prescribed by TCM practitioners for the treatment of hepatitis are listed in [Table 6](#tab6){ref-type="table"}. The three most frequently prescribed single herbs were *Salvia miltiorrhiza*, *Corydalis yanhusuo*, and *Radix et Rhizoma Rhei*. The average days of prescription for single herbs ranged from 7.1 to 9.2 days. The three most frequently prescribed formulas were Jia-Wei-Xiao-Yao-San (JWXYS), Xiao-Chai-Hu Tang (XCHT), and Shu-Jing-Huo-Xue-Tan (SJHXT). The average days of prescription for formulas ranged from 7 to 9 days, very similar to single herbs. To clarify the association between CHM and CKD, the top ten single herbs and formulas for each hazard ratio of developing CKD are presented in [Table 7](#tab7){ref-type="table"}. Except *Astragali Radix*, Ban-Xia-Xie-Xin-Tang, and Long-Dan-Xie-Gan-Tang, the single herbs and formulas led to significant lower risk of developing CKD (all of *p* \< 0.05). A network analysis of the thirty most frequently prescribed single herbs and formula combinations is shown in [Figure 3](#fig3){ref-type="fig"}, revealing JWXYS and *SM*, as well as *Olibanum* and *Myrrha* as the most frequent combinations.

4. Discussion {#sec4}
=============

This is the first large-scale nationwide cohort study exploring the association between CHM therapy and incidence of CKD in hepatitis patients. The results of the study reveal that CHM, as an adjuvant therapy for patients with hepatitis, indeed offered protective effects and prevented the development of CKD, particularly in the HCV subtype.

There are several mechanisms at play in hepatitis patients. In particular, HBeAg is prone to combine with host antibodies, forming an immune-complex which affects renal function and induces the inflammatory process resulting in secondary MN, the most common renal manifestation in patients with HBV \[[@B17]\]. Approximately 40% to 50% of MN in adults results in nephrotic syndrome, eventually progressing to ESRD within a period of 6 to 13 years \[[@B18]\]. Thus, HBeAg seroconversion may be critical in the prevention of renal damage. As reported by Chen et al., HBV patients without NAs treatment will more easily develop ESRD \[[@B19]\]. Meanwhile, HCV can induce renal dysfunction via direct infection of kidney tissue, lymphotropism, and cryoglobulinemia \[[@B10]\]. HCV directly infects kidney tissue via CD81 expression on its surface to induce cell apoptosis \[[@B20]\]. Type II mixed cryoglobulinemia, originating from IgG-IgM complexes, is the primary manifestation in HCV patients, predominantly inducing type I membranoproliferative glomerulonephritis (MPGN) as a result of cryoglobulinemic vasculitis \[[@B10], [@B21]\]. The prevalence of type II mixed cryoglobulinemia-dependent MPGN in CHC patients is approximately 30% \[[@B22]\] and is considered the most common cause of nephritic or nephrotic syndrome \[[@B23]\]. In a large-scale cohort study (*n* = 56,448), CHC patients demonstrated an approximately 2-fold and 17-fold risk of developing MPGN and cryoglobulinemia, respectively \[[@B24]\]. Thus, antiviral therapy may be a superior option to protect kidneys by preventing viral proliferation and synthesis of immune-complexes, decreasing immune-complex and cryoglobulin formations, as well as preventing inflammation and vasculitis.

The present study explores the risk factors associated with CKD development in patients with hepatitis, such as male gender, age over 60, hypertension, DM, liver cirrhosis, and heart failure. Moreover, while HCV, CKD, and statin medications can decrease the risk of developing CKD, and DM medications, by contrast, can increase the risk. As previously reported, male gender and age are the primary risk factors associated with the development of MN, while the average onset of MN was in patients\' 50s and 60s of age, compatible with the findings of this study \[[@B18]\]. Meanwhile, hypertension exerts negative effects on the kidneys as it leads to increased intraglomerular capillary pressure, podocyte dysfunction, abnormal permeability, and eventual proteinuria. This mechanism can be prevented via angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) \[[@B25]\].

The development of MN or MPGN caused by hepatitis viral infection will lead to nephrotic syndrome, associated with proteinuria. The protein loss results in a decrease of oncotic pressure, and hypoproteinemia will be compensated for by liver genesis lipoprotein; consequently, excess production of low density lipoprotein causes hypercholesteremia. However, hypocholesteremia has been observed in HCV patients due to upregulated lipid biosynthesis and impaired lipid degradation, which leads to intracellular lipid accumulation and facilitates the formation of steatosis and fibrosis \[[@B26]\]. This phenomenon will induce hypoproteinemia and affect the cardiovascular system as a result of hypertension and/or congestive heart failure, becoming risk factors of CKD development in patients with hepatitis. Statin has been reported to control hyperlipidemia, exert powerful anti-HCV effects, and thus reduce the risk of cirrhosis in hepatitis patients \[[@B27]\].

Additionally, DM is a common extrahepatic manifestation associated with HCV infection \[[@B22]\]. The HCV core protein decreases the expression of insulin receptor substrate proteins (IRS) 1 and 2 and causes abnormal insulin sensitivity and beta-cell dysfunction. As such, it activates insulin resistance and hyperinsulinemia, consequently inducing HCV-related diabetic nephropathy \[[@B20]\]. Many DM drug metabolites are eliminated via the kidneys, such as biguanide, sulphonylureas, dipeptidylpeptidase-4 inhibitors, and SGLT-2 inhibitors, possibly burdening renal function \[[@B28]\].

Based on the top 10 most frequently prescribed formulas and single herbs, CHM may prevent CKD incidence among hepatitis patients via directly inhibiting viral expression, preventing liver and kidney damage, treating the comorbidities, and alleviating the side effects induced by interferon. HBV and/or HCV infection will activate the inflammatory process, leading to fibrosis and cirrhosis. According to TCM theory, these phenomena are primarily patterned as hepatobiliary damp-heat. Among the top ten herbs and formulas, XCHT, *Radix et Rhizoma Rhei*, *Radix astragali*, and *Scutellaria radix* exert anti-HBV activity, while XCHT has exhibited anti-HCV activity in a phase II clinical trial \[[@B29]\].

The effects of cryoglobulinemia and immune-complexes cause renal function decline. These, according to TCM theory, can be considered consistent with Qi stagnation and blood stasis. Several CHM herbs and formulas may offer protective effects against both liver and renal function decline. In particular, TCM theory suggests that JWXYS and Xue-Fu-Zhu-Yu-Tang (XFZYT) may serve to soothe liver Qi and relieve blood stasis. Studies have reported that JWXYS may improve the survival rate in HBV patients when combined with lamivudine treatment \[[@B30]\] and decrease the mortality rate and risk of liver cirrhosis in HCV patients \[[@B31]\]. Furthermore, JWXYS has been shown to elevate serum albumin levels and prevent liver fibrosis \[[@B32]\]. Meanwhile, TCM theory suggests that *SM*, the most commonly prescribed herb identified in this study, can invigorate blood, dispel blood stasis, and cool blood heat. Furthermore, it has been reported that *SM* prevents immune-mediated liver injury and liver fibrosis through modulating the NF-κB and IFN-γ/STAT1 signaling pathways as well as enhancing NK cell activity \[[@B33]\]. Of note, a recent study revealed renal fibrosis resulting from MN and diabetic nephropathy via the dysregulation of the TGF-*β*/Smad pathway \[[@B34]\]. This pathway can be regulated by *SM* and *Scutellaria radix* to protect renal function from deterioration \[[@B35]\].

On the aspect of treating the comorbidities, XFZYT has not only antiangiogenesis effect that can prevent liver fibrosis \[[@B36]\] but also lowers the blood pressure \[[@B37]\]. *Pueraria lobate* exerts anti-inflammation effects through regulating the IKKb/IRS-1 pathway and improving endothelial insulin resistance. When combined with *SM*, the synergistic effects of antihypertension and antiatherosclerosis may effectively reduce the risk of CKD \[[@B38], [@B39]\]. This correlation was further observed in the network analysis herein. SM alone can also prevent the development of DM nephropathy via suppressing TGF-*β*1 and improving renal microcirculation \[[@B40]\].

Other herbal formulas without direct hepatic and renal protective activities may help deal with the interferon side effects. Some HCV patients undergoing pegylated interferon/ribavirin therapy will seek CHM to alleviate side effects and improve quality of life \[[@B41]\]. The common side effects of PEG-IFN include flu-like symptoms (headache, myalgia, and fatigue); digestive discomforts (nausea, loss of appetite, and diarrhea); and neuropsychiatric disorders (insomnia and depression) \[[@B42]\]. Shu-Jing-Huo-Xue-Tang and Shao-Yao-Gan-Cao-Tang have been reported to increase blood circulation and decrease muscle cramps to relieve myalgia \[[@B43], [@B44]\]. Ban-Xia-Xie-Xin-Tang possesses prokinetic activity and motility regulation to alleviate anorexia and diarrhea \[[@B45]\]. JWXYS and Suan-Zao-Ren-Tang improve insomnia and depression \[[@B46]\]. The other known pharmacological mechanisms of the top ten single herbs and formulas are illustrated in Supplementary Tables [](#supplementary-material-1){ref-type="supplementary-material"} and [](#supplementary-material-1){ref-type="supplementary-material"}.

Although the new generation of NAs and DAAs provides hepatitis patients with effective treatment options, high costs may restrict their popularity and availability, particularly in developing countries. By contrast, CHM treatments offer more cost-effective management strategies. This study demonstrates that CHM provided protective effects against development of CKD for HCV patients. Therefore, the use of CHM as an adjuvant therapy strategy warrants consideration by medical practitioners.

Inevitably, the analysis of data extracted from the NHIRD has limitations. First, laboratory data, images, pathology reports, and patient lifestyle details are not recorded in the database. Second, the diagnostic records were based on ICD-9, which lacks data regarding CKD severity; ICD-10 provides more information (ICD-10 code: N181--N189) regarding the severity of CKD. Third, some CKD risk factors, such as proteinuria, smoking, herbal supplement therapy, intravenous drug use, and human immunodeficiency virus infection were not included in this study. Fourth, we did not exclude the influence from hepatitis D virus infection among CHB groups. Furthermore, patients\' CHM compliance cannot be shown by NHIRD.

5. Conclusions {#sec5}
==============

The database analysis of this study reveals that CHM as an adjunctive therapy decreased incidence of CKD in Taiwanese patients with hepatitis C. These findings suggest that future research into complementary and alternative medicine treatments for patients with hepatitis C is warranted. However, future prospective cohort research is recommended to ascertain and elucidate the specific CHM mechanisms associated with CKD prevention in hepatitis patients.
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###### 

Supplementary Table 1: incidence rates, hazard ratio, and confidence intervals of CKD in different stratifications correlated with comorbidities. Multivariable stratified analyses were applied to verify the association of hepatitis patients with CHM treatment to reduce CKD risk for those comorbidities. Supplementary Table 2: the hepatic and renal protective activities associated with experimental models of extracted ingredients of single herbs. The known pharmacological mechanisms of the top ten single herbs were associated with liver and renal protection by cell and/or animal experimental studies. Supplementary Table 3: the compositions as well as hepatic and renal protective activities associated with experimental models of top ten formulas. The compositions and hepatic protection of the top ten formulas were illustrated.

###### 

Click here for additional data file.

![Flow chart of study cases (Chinese herbal medicine, CHM) from the Longitudinal Health Insurance Database (LHID) in Taiwan, from years 2000 to 2010.](ECAM2019-5319456.001){#fig1}

![Cumulative incidence of CKD of both CHM and non-CHM cohorts in patients with hepatitis, by Kaplan--Meier analysis.](ECAM2019-5319456.002){#fig2}

![Network analysis of the 30 most frequently prescribed herbs and formulas for patients with hepatitis. The spot size indicates the frequency of Chinese herbal product prescription, and the line width indicates the combination frequency between two Chinese herbal products.](ECAM2019-5319456.003){#fig3}

###### 

Characteristics of hepatitis patients with and without CHM.

  Characteristic            CHM           *p* value      
  ------------------------- ------------- -------------- ------
  *Gender^∗^*                                            0.09
  Female                    1094 (40.4)   1033 (38.1)     
  Male                      1616 (59.6)   1677 (61.9)     
                                                         
  *Age, year* ^*†*^                                      0.01
  18--44                    926 (34.2)    828 (30.6)      
  45--59                    873 (32.2)    972 (35.9)      
  ≥60                       911 (33.6)    910 (33.6)      
  Mean (SD)                 53.2 (16.1)   53.2 (14.58)   0.97
                                                         
  *Urbanization^∗^*                                      0.29
  1 (highest)               677 (25)      646 (23.8)      
  2                         792 (29.2)    835 (30.8)      
  3                         409 (15.1)    437 (16.1)      
  4 (lowest)                832 (30.7)    792 (29.2)      
                                                         
  *Comorbidity^∗^*                                        
  Hypertension              1124 (41.5)   1117 (41.2)    0.85
  Diabetes mellitus         769 (28.4)    751 (27.7)     0.59
  Coronary artery disease   734 (27.1)    723 (26.7)     0.74
  Hyperlipidemia            789 (29.1)    776 (28.6)     0.7
  Liver cirrhosis           474 (17.5)    457 (16.9)     0.54
  Heart failure             123 (4.5)     113 (4.2)      0.51
  Osteoporosis              367 (13.5)    359 (13.2)     0.75
  Arrhythmia                310 (11.4)    289 (10.7)     0.36
  PVD                       66 (2.4)      65 (2.4)       0.93
                                                         
  *Medication^∗^*                                         
  HBV drug                  121 (4.5)     123 (4.5)      0.9
  HCV drug                  177 (6.5)     165 (6.1)      0.5
  CKD drug                  1512 (55.8)   1491 (55)      0.57
  DM drug                   467 (17.2)    474 (17.5)     0.8
  Statin                    320 (11.8)    315 (11.6)     0.83

^∗^Chi-squared test; ^†^*t*-test. Abbreviations: CHM, Chinese herbal medicine; SD, standard deviation; PVD, peripheral vascular disease; HBV, hepatitis B virus; hepatitis C virus; CKD, chronic kidney disease; DM, diabetes mellitus.

###### 

Risk factors of CKD among hepatitis patients.

  Variable                  CKD   Crude   Adjusted^§^                                    
  ------------------------- ----- ------- -------------- --------- ------ -------------- ---------
  *CHM*                                                                                   
  No                        318   1       (Reference)              1      (Reference)     
  Yes                       452   0.8     (0.69--0.93)   0.004     0.69   (0.59--0.8)    \<0.001
                                                                                         
  *Gender*                                                                                
  Female                    312   1       (Reference)              1      (Reference)     
  Male                      458   0.9     (0.78--1.04)   0.14      1.26   (1.08--1.48)   0.003
                                                                                         
  *Age, year*                                                                             
  18--44                    108   1       (Reference)              1      (Reference)     
  45--59                    240   2.31    (1.84--2.9)    \<0.001   2.12   (1.67--2.69)   \<0.001
  ≥60                       422   4.81    (3.89--5.94)   \<0.001   3.59   (2.78--4.64)   \<0.001
                                                                                         
  *Urbanization*                                                                          
  1 (highest)               164   1       (Reference)              1      (Reference)     
  2                         227   1.1     (0.9--1.35)    0.35      1.12   (0.91--1.37)   0.29
  3                         109   1.02    (0.8--1.3)     0.89      0.98   (0.77--1.25)   0.85
  4 (lowest)                270   1.39    (1.14--1.68)   \<0.001   1.14   (0.93--1.38)   0.21
                                                                                         
  *Comorbidity*                                                                           
  Hypertension              460   2.49    (2.16--2.88)   \<0.001   1.36   (1.14--1.62)   \<0.001
  Diabetes mellitus         360   2.59    (2.25--2.99)   \<0.001   1.55   (1.31--1.84)   \<0.001
  Coronary artery disease   303   2.05    (1.78--2.37)   \<0.001   1.12   (0.95--1.33)   0.18
  Hyperlipidemia            286   1.59    (1.37--1.84)   \<0.001   1.13   (0.96--1.32)   0.14
  Liver cirrhosis           180   2.02    (1.71--2.39)   \<0.001   1.54   (1.29--1.83)   \<0.001
  Heart failure             65    2.84    (2.2--3.66)    \<0.001   1.61   (1.23--2.11)   \<0.001
  Osteoporosis              147   1.74    (1.45--2.08)   \<0.001   0.99   (0.82--1.21)   0.96
  Arrhythmia                112   1.57    (1.29--1.92)   \<0.001   0.97   (0.78--1.2)    0.78
  PVD                       23    1.49    (0.98--2.26)   0.06      0.96   (0.63--1.46)   0.85
                                                                                         
  *Medication*                                                                            
  HBV drug                  22    0.68    (0.45--1.04)   0.08      0.73   (0.47--1.12)   0.15
  HCV drug                  29    0.44    (0.3--0.63)    \<0.001   0.45   (0.31--0.65)   \<0.001
  CKD drug                  557   1.86    (1.58--2.17)   \<0.001   0.78   (0.65--0.95)   0.01
  DM drug                   253   2.24    (1.93--2.6)    \<0.001   1.41   (1.18--1.68)   \<0.001
  Statin                    112   1.09    (0.89--1.33)   0.4       0.7    (0.56--0.86)   \<0.001

CHM, Chinese herbal medicine; SD, standard deviation; PVD, peripheral vascular disease; HBV, hepatitis B virus; hepatitis C virus; CKD, chronic kidney disease; DM, diabetes mellitus; HR, hazard ratio; CI, confidence interval. ^§^Cox model adjusted with gender, age, urbanization, comorbidity and medication.

###### 

The CHM effect on CKD in subgroups.

  Subgroup      Non-CHM users   CHM users   Crude HR (95%)   Adjusted HR (95%)^§^                                           
  ------------- --------------- ----------- ---------------- ---------------------- ------ ------ ------------------------- -------------------------
  HBV           111             4216        2.63             134                    5562   2.41   0.89(0.69--1.15)          0.81(0.62--1.05)
  HCV           153             3384        4.52             281                    8637   3.25   0.72 (0.59--0.88)^*∗∗*^   0.65 (0.53--0.8)^*∗∗∗*^
  HBV and HCV   54              1469        3.68             37                     1334   2.77   0.75 (0.49--1.14)         0.6 (0.39--0.92)^*∗*^

HBV, hepatitis B virus; hepatitis C virus; PY, person year; IR, incidence rate/per 100 person-years; HR, hazard ratio; CI, confidence interval. ^§^Cox model adjusted with gender, age, urbanization, comorbidity, and medication. ^*∗*^*p* \< 0.05; ^*∗∗*^*p* \< 0.01; ^*∗∗∗*^*p* \< 0.001.

###### 

Cox proportional hazard regression analysis for the risk of CKD for HBV and HCV medication.

  Variable                 Number     CKD event   Person years   IR     Crude HR (95% CI)   Adjusted HR (95% CI)       
  ------------------------ ---------- ----------- -------------- ------ ------------------- -------------------------- -------------------------
  *HBV patients*                                                                                                       
  CHM                      HBV drug                                                                                     
  No                       No         1169        107            4054   2.64                Ref.                       Ref.
  No                       Yes        1080        134            5431   2.47                0.91 (0.71--1.18)          0.84 (0.65--1.10)
  Yes                      No         36          4              163    2.45                0.92 (0.34--2.50)          0.98 (0.36--2.67)
  Yes                      Yes        23          0              132    0.00                ---                        ---
                                                                                                                       
  *HCV patients*                                                                                                       
  CHM                      HCV drug                                                                                     
  No                       No         966         148            3100   4.77                Ref.                       Ref.
  No                       Yes        1172        271            8060   3.36                0.70 (0.57--0.86)^*∗∗∗*^   0.66 (0.53--0.81)^*∗∗*^
  Yes                      No         58          5              284    1.76                0.37 (0.15--0.89)^*∗*^     0.52 (0.21--1.28)
  Yes                      Yes        78          10             577    1.73                0.36 (0.19--0.68)^*∗∗*^    0.40 (0.21--0.76)^*∗∗*^
                                                                                                                       
  *HCV and HBV patients*                                                                                               
  CHM                      Both                                                                                         
  No                       No         420         48             1258   3.82                Ref.                       Ref.
  No                       Yes        325         35             1204   2.91                0.76 (0.49--1.18)          0.69 (0.44--1.09)
  Yes                      No         48          4              154    2.59                0.68 (0.25--1.89)          0.69 (0.24--1.97)
  Yes                      Yes        20          2              82     2.43                0.63 (0.15--2.57)          0.81 (0.19--3.39)

IR, incidence rates, HR, hazard ratio; CI, confidence interval. Adjusted HR: adjusted for sex, age, and all comorbidites in Cox proportional hazards regression. ^*∗*^*p* value \<0.05; ^*∗∗*^*p* value \<0.01; ^*∗∗∗*^*p* value \<0.001.

###### 

Hazard Ratios and 95% confidence intervals of CKD risk associated with cumulative use day of TCM among hepatitis patients.

  -------------------------------------------------------------------------------------------------------------
                       Event no.\    Person year   IR     Hazard ratio (95% CI)      
                       (*n* = 770)                                                   
  -------------------- ------------- ------------- ------ -------------------------- --------------------------
  Non-TCM users        318           9069          3.51   1.00 (ref.)                1.00 (ref.)

  Chinese herb users                                                                  

   30--60 days         144           4045          3.56   0.99 (0.81--1.20)          0.88 (0.72--1.07)

   60--90 days         74            2253          3.28   0.91 (0.71--1.17)          0.82 (0.64--1.06)

   \>90 days           234           9236          2.53   0.70 (0.58--0.83)^*∗∗∗*^   0.58 (0.49--0.69)^*∗∗∗*^

   *p* for trend                                                                     *p* \< 0.001
  -------------------------------------------------------------------------------------------------------------

Crude HR^*∗*^ represented relative hazard ratio; adjusted HR^†^ represented adjusted hazard ratio: mutually adjusted with gender, age, urbanization, comorbidity, and medication in Cox proportional hazard regression. ^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.01, ^*∗∗∗*^*p* \< 0.001.

###### 

The top ten single herbs and formulas.

                                     Frequency   Total prescription days   Total prescription dose   Average dose   Average days
  ---------------------------------- ----------- ------------------------- ------------------------- -------------- --------------
  *Single herb*                                                                                                      
  *Salviae Miltiorrhizae*            18286       167551                    421569.9                  2.5            9.2
  *Corydalis Rhizoma*                15145       107063                    291003.8                  2.7            7.1
  *Rhei Radix et Rhizoma*            11676       91721                     132202.1                  1.4            7.9
  *Scutellariae Radix*               11294       88082                     233831.4                  2.7            7.8
  *Astragali Radix*                  9310        82461                     193854.9                  2.4            8.9
  *Fritillariae Thunbergii Bulbus*   11204       81940                     216510.7                  2.6            7.3
  *Platycodonis Radix*               11343       76509                     156414.6                  2              6.7
  *Puerariae Lobatae Radix*          10186       73121                     166687.3                  2.3            7.2
  *Polygoni Multiflori Thunb*        8094        69468                     208078.5                  3              8.6
  *Ziziphi Spinosae Semen*           8013        69061                     312031.1                  4.5            8.6
                                                                                                                    
  *Formula*                                                                                                          
  Jia-Wei-Xiao-Yao-San               17136       153716                    1408374                   9.2            9
  Xiao-Chai-Hu Tang                  11782       93309                     1008159                   10.8           7.9
  Shu-jing-huo-xue-tang              12959       90749                     899737.6                  9.9            7
  Ban-Xia-Xie-Xin-Tang               11630       87996                     942883.3                  10.7           7.6
  Shao-Yao-Gan-Cao-Tang              10471       70062                     585790.8                  8.4            6.7
  Long-Dan-Xie-Gan-Tang              8580        69280                     769180.1                  11.1           8.1
  Suan-Zao-Ren-Tang                  9241        69113                     760566.7                  11             7.5
  Xue-Fu-Zhu-Yu-Tang                 8577        67528                     528117.1                  7.8            7.9
  Xiang-Sha-Liu-Jun-Zi-Tang          8040        66951                     499931.6                  7.5            8.3
  Ping-Wei-San                       8777        65916                     522327.2                  7.9            7.5

###### 

Hazard ratios and 95% confidence intervals of mortality risk associated with herbal formulas among hepatitis patients.

  TCM prescription                   CKD   Hazard ratio (95% CI)     
  ---------------------------------- ----- ------------------------- -------------------------
  Non-TCM user                       318   Ref.                      Ref.
  *Single herb*                                                       
  *Salviae Miltiorrhizae*            201   0.92 (0.77--1.11)         0.73 (0.61--0.89)^*∗∗*^
  *Corydalis Rhizoma*                194   0.87 (0.72--1.05)         0.74 (0.61--0.89)^*∗∗*^
  *Rhei Radix et Rhizoma*            108   0.95 (0.76--1.18)         0.75 (0.60--0.95)^*∗*^
  *Scutellariae Radix*               145   0.76 (0.62--0.94)^*∗∗*^   0.72 (0.58--0.89)^*∗∗*^
  *Astragali Radix*                  127   1.00 (0.81--1.24)         0.83 (0.67--1.03)
  *Fritillariae Thunbergii Bulbus*   152   0.84 (0.69--1.03)         0.74 (0.60--0.91)^*∗∗*^
  *Platycodonis Radix*               153   0.95 (0.78--1.15)         0.81 (0.66--0.99)^*∗*^
  *Puerariae Lobatae Radix*          143   0.82 (0.67--1.00)         0.71 (0.58--0.88)^*∗∗*^
  *Polygoni Multiflori Thunb*        93    0.80 (0.63--1.01)         0.69 (0.54--0.88)^*∗∗*^
  *Ziziphi Spinosae Semen*           96    0.86 (0.68--1.08)         0.76 (0.59--0.96)^*∗*^
                                                                     
  *Formula*                                                           
  Jia-Wei-Xiao-Yao-San               150   0.85 (0.69--1.03)         0.80 (0.65--0.99)^*∗*^
  Xiao-Chai-Hu Tang                  165   0.87 (0.72--1.06)         0.74 (0.60--0.90)^*∗*^
  Shu-jing-huo-xue-tang              196   0.91 (0.76--1.09)         0.75 (0.62--0.91)^*∗∗*^
  Ban-Xia-Xie-Xin-Tang               145   0.96 (0.78--1.17)         0.82 (0.66--1.01)
  Shao-Yao-Gan-Cao-Tang              162   0.80 (0.66--0.98)^*∗*^    0.69 (0.57--0.85)^*∗∗*^
  Long-Dan-Xie-Gan-Tang              123   0.96 (0.77--1.19)         0.81 (0.65--1.01)
  Suan-Zao-Ren-Tang                  106   0.80 (0.64--1.01)         0.72 (0.57--0.91)^*∗∗*^
  Xue-Fu-Zhu-Yu-Tang                 144   0.91 (0.74--1.12)         0.75 (0.61--0.93)^*∗∗*^
  Xiang-Sha-Liu-Jun-Zi-Tang          118   0.86 (0.69--1.06)         0.67 (0.54--0.84)^*∗∗*^
  Ping-Wei-San                       113   0.81 (0.65--1.01)         0.68 (0.54--0.85)^*∗∗*^

Crude HR^*∗*^ represented relative hazard ratio; adjusted HR^†^ represented adjusted hazard ratio: mutually adjusted for age group, gender, urbanization level, and cci score in Cox proportional hazard regression. ^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.01, ^*∗∗∗*^*p* \< 0.001.

[^1]: Academic Editor: I-Min Liu
